EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access

Efficacy and Safety of Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, and Janus Kinase Inhibitors in Patients with Non-Radiographic Axial Spondyloarthritis: A Systematic Review and Network Meta-Analysis

Dan Li, Xinhui Zhang, Yunfei Tian, Jing Zhang, Xiaojuan Zhao, Menghao Li, Yonghong Zhao, Xiuju Liu

International Archives of Allergy and Immunology · 10.12.2024 · 186 (8) · 784-801

DOI: 10.1159/000542744 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 10.12.2024. Verfasst von Dan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Antirheumatic Agents, Axial Spondyloarthritis, Interleukin-17, Janus Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to systematically assess the efficacy and safety of tumor necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), and Janus kinase inhibitors (JAKi) in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Methods

A systematic literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Register of Clinical Trials, and Scopus to find randomized controlled trials in patients with nr-axSpA published until June 2023. Stata 17.0 software and Review Manager 5.4 software were used for data analysis. The results for binary and continuous variables were expressed as the values of odds ratio and mean difference and their 95% confidence interval, respectively.

Results

For Assessment of SpondyloArthritis International Society Response Criteria for 40% improvement (ASAS40), the efficacy of the 12 interventions ranked as follows: certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W) > CZP 400 mg Q4W > golimumab (GOL) > bimekizumab (BKZ) > adalimumab (ADA) > upadacitinib (UPA) > etanercept (ETN) > brodalumab (BRO) > ixekizumab (IXE) > secukinumab (SEC) 150 mg no loading (NL) > SEC 150 mg loading dose (LD) > placebo (PBO). For assessment of ASAS20, the NMA results were ranked as follows: GOL > CZP 400 mg Q4W> BKZ> ADA > UPA > CZP 200 mg Q2W > ETN > BRO > SEC 150 mg NL > SEC 150 mg LD > PBO, and GOL > ADA > PBO > UPA > SEC 150 mg NL > BKZ > IXE > SEC 150 mg LD > ETN > CZP 200 mg Q2W for adverse events.

Conclusions

Most TNFi may be more effective than JAKi and IL-17i. They were all well tolerated. However, the efficacy and safety of TNFi/IL-17i/JAKi remain to be further analyzed in studies with larger sample sizes and longer follow-up times.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsAxial SpondyloarthritisInterleukin-17Janus Kinase InhibitorsTumor Necrosis Factor InhibitorsHumansTreatment Outcome

Stichwörter der Autor:innen

EfficacyInterleukin-17 inhibitorsJanus kinase inhibitorsNetwork meta-analysisNon-radiographic axial spondyloarthritisSafetyTumor necrosis factor inhibitors

Substanzen

Antirheumatic AgentsInterleukin-17Janus Kinase InhibitorsTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Psychology, The University of Hong Kong, Hong Kong, Hong Kong, China.
  • Department of Clinical Pharmacy, Hebei Medical University, Shijiazhuang, China.

Zitieren

APA

Li, D., Zhang, X., Tian, Y., Zhang, J., Zhao, X., Li, M., Zhao, Y., & Liu, X. (2024). Efficacy and Safety of Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, and Janus Kinase Inhibitors in Patients with Non-Radiographic Axial Spondyloarthritis: A Systematic Review and Network Meta-Analysis. International Archives of Allergy and Immunology, 186(8), 784-801. https://doi.org/10.1159/000542744

Vancouver

Li D, Zhang X, Tian Y, Zhang J, Zhao X, Li M, et al. Efficacy and Safety of Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, and Janus Kinase Inhibitors in Patients with Non-Radiographic Axial Spondyloarthritis: A Systematic Review and Network Meta-Analysis. International Archives of Allergy and Immunology. 2024;186(8):784-801. doi:10.1159/000542744

BibTeX
@article{Li2024,
  author = {Li, Dan and Zhang, Xinhui and Tian, Yunfei and Zhang, Jing and Zhao, Xiaojuan and Li, Menghao and Zhao, Yonghong and Liu, Xiuju},
  title = {Efficacy and Safety of Tumor Necrosis Factor Inhibitors, Interleukin-17 Inhibitors, and Janus Kinase Inhibitors in Patients with Non-Radiographic Axial Spondyloarthritis: A Systematic Review and Network Meta-Analysis},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  volume = {186},
  number = {8},
  pages = {784--801},
  doi = {10.1159/000542744}
}
Kostenlos starten →